Brief: Biocryst Pharmaceuticals: FDA Extends PDUFA Goal Date For Orladeyo NDA
25/06/2025 11:59
June 25 (Reuters) - BioCryst Pharmaceuticals Inc BCRX.O: BIOCRYST PHARMACEUTICALS INC - ON JUNE 23, FDA EXTENDS PDUFA GOAL DATE FOR ORLADEYO NDA - SEC FILING BIOCRYST PHARMACEUTICALS INC - NEW PDUFA TARGET ACTION DATE SET FOR DECEMBER 12, 2025 - SEC FILING Source text: [ID:n0001171843-25-004091] Further company coverage: BCRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioCryst Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
Brief: Biocryst Announces Approval Of Orladeyo® For Pediatric Hae Patients In Japan
BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Biocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026